Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Auteurs : Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, OKeeffe B, Shapiro GI, Winer EP
Année : 2016
Journal : Breast Cancer Res Treat
Volume : 160
Pages : 305-312